Compass Pathways Appoints a New CEO
George Goldsmith will be replaced as Compass Pathways CEO. Is this good or bad news?
James Hallifax is an entrepreneur who co-founded The Psychedelic Investor, a media company focused on investing in psychedelic medicines which treat mental health conditions. Together with his business partner, they have grown their YouTube Channel to be the largest Channel dedicated to Investing in Psychedelics. Through their partnership with Psychedelic Spotlight, James aims to help educate retail investors on the potential for substances like LSD, MDMA and Magic Mushrooms to heal, and for early investors who make the right choices to make a lot of money. Rather than focus on day to day stock movements, James follows the underlying science of the industry, to help people understand which companies are the most likely to succeed long term.
George Goldsmith will be replaced as Compass Pathways CEO. Is this good or bad news?
Deficiancies in good clinical practices and accurate record keeping stops an MDMA clinical trial in its tracks
The Netflix documentary ‘How to Change Your Mind' is great TV even though it fails to provide balanced coverage of psychedelics
People around the world are learning about the mental health benefits of psychedelics. Here are 5 countries where psychedelics are legal.
Michael Pollan's landmark book is now a streaming miniseries, but is the Netflix psychedelics documentary worth the watch?
Psychedelic companies rely on novel patents to boost their value, but many players in the space are chasing the same IP
As psychedelics continue to gain mainstream acceptance, these 5 states have started the process to legalize psychedelics
This week in psychedelic stock news: MindMed downplays delisiting fears; Red Light Holland teams with Wiz Khalifa; Field Trip shareholders approve company split; and more!
In a Reddit AMA, MindMed CEO Robert Barrow says Nasdaq delisting is not “a risk of any sort.”
A Colorado initiative gives voters the power to legalize psychedelics and psilocybin therapy this November.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.